Alphamab Oncology (ALPHAMAB-B) reported a marginal reduction in its outstanding equity for the month ended 31 August 2026, driven entirely by a treasury share buy-back executed on the last trading day of the month.

Key figures for August 2026 • Authorised share capital: unchanged at 25.10 billion ordinary shares (USD 50,200). • Total issued shares: steady at 974.38 million, comprising 968.40 million in public hands and 5.99 million held as treasury. • Movement in issued shares (ex-treasury): –110,000 shares; movement in treasury shares: +110,000 shares. • Buy-back details: 110,000 shares repurchased on 31 August 2026 at HKD 8.901 per share, totalling approximately HKD 0.98 million. • Public float: above the 25 % minimum requirement under Main Board Rule 13.32B.

Equity incentive schemes • Pre-IPO Share Option Plan I: 42,000 options cancelled; 9.17 million options remain outstanding. • Pre-IPO Share Option Plan II: no changes; 4.84 million options outstanding. • Post-IPO Share Option Plan: 8,000 options lapsed; 0.85 million options remain outstanding with capacity to issue up to 95.40 million additional shares under the refreshed mandate approved on 12 June 2024. • No new shares were issued and no treasury shares were transferred under any option or award scheme during the month, resulting in zero funds raised from employee equity exercises.

Capital structure snapshot (31 Aug 2026) • Issued shares (ex-treasury): 968.40 million • Treasury shares: 5.99 million • Total issued shares: 974.38 million

The company confirmed compliance with all Hong Kong Exchange listing rules and noted that the buy-backs were duly authorised by the board at the 12 June 2026 general meeting.